Top FDA staffer becomes third to resign since August

An FDA official, whose office was involved in the recent controversial approval review of Bristol-Myers Squibb's Pargluva, has announced his resignation to join private industry, The New York Times reports.
David Orloff, a division director who oversees the review of drugs to treat metabolic and endocrine disorders, is set to join Medpace, a contract research organization that runs clinical drug trials.
Orloff told the Times his decision to leave after 11 years at the FDA, with five of them as division director, was not related to any problems or frustrations, but reflected a new opportunity. 
Orloff's departure from the FDA will be the third by a ranking agency official since the summer. In September, FDA commissioner Lester Crawford resigned for reasons yet to be fully explained, and in August, Susan Wood, the agency's top women's health official, resigned in protest over delays in an approval decision for the OTC sale of Barr's Plan B contraceptive

You must be a registered member of MMM to post a comment.

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.